MUC1作为乳腺癌免疫治疗靶点的研究进展

Advances of MUC1 as a target for breast cancer immunotherapy.

作者信息

Yang E, Hu X F, Xing P X

机构信息

Cancer Immunotherapy Laboratory, Burnet Institute incorporating Austin Research Institute, Heidelberg, Victoria, Australia.

出版信息

Histol Histopathol. 2007 Aug;22(8):905-22. doi: 10.14670/HH-22.905.

DOI:10.14670/HH-22.905

PMID:17503348

Abstract

MUC1 is a potential target in breast cancer immunotherapy as MUC1 is overexpressed in breast cancer, and is absent or expressed in low level in normal mammary gland. In addition, MUC1 is mostly aberrantly underglycosylated in cancer and the antigens on the cancer surface are different from normal cell. Therefore targeting MUC1 for cancer immunotherapy can exploit the difference between cancer and normal cells, and eliminating the cancerous cells while leaving the normal mammary cells unharmed. This review will focus on the recent advance of MUC1 breast cancer immunotherapy currently being investigated.

摘要

粘蛋白1（MUC1）是乳腺癌免疫治疗的一个潜在靶点，因为MUC1在乳腺癌中过表达，而在正常乳腺组织中不存在或低水平表达。此外，MUC1在癌症中大多发生异常低糖基化，癌症表面的抗原与正常细胞不同。因此，针对MUC1进行癌症免疫治疗可以利用癌症细胞与正常细胞之间的差异，在不损害正常乳腺细胞的情况下消除癌细胞。本综述将聚焦于目前正在研究的MUC1乳腺癌免疫治疗的最新进展。